Daily Ards Research Analysis
Today’s top studies span neonatal respiratory support, integrated therapies for pancreatitis-related ARDS, and extubation prognostication in COVID-19 ARDS. A delivery-room RCT supports prioritizing higher nCPAP PEEP over oxygen escalation, a meta-analysis suggests CHM plus Western care improves inflammatory and clinical surrogates in SAP-ALI/ARDS without mortality benefit, and a cohort study shows serial cardiac/inflammatory biomarkers add little prognostic value for extubation failure.
Summary
Today’s top studies span neonatal respiratory support, integrated therapies for pancreatitis-related ARDS, and extubation prognostication in COVID-19 ARDS. A delivery-room RCT supports prioritizing higher nCPAP PEEP over oxygen escalation, a meta-analysis suggests CHM plus Western care improves inflammatory and clinical surrogates in SAP-ALI/ARDS without mortality benefit, and a cohort study shows serial cardiac/inflammatory biomarkers add little prognostic value for extubation failure.
Research Themes
- Optimization of non-invasive respiratory support in the delivery room
- Integrated Chinese-Western therapies for pancreatitis-related ARDS
- Biomarker-based prediction of extubation outcomes in ARDS
Selected Articles
1. Non-invasive open lung strategy in delivery room: randomized controlled trial (OpenCPAP-DR).
In a randomized delivery-room trial of very preterm infants, initiating nCPAP at 6 cmH2O and prioritizing PEEP escalation over oxygen increase helped achieve target oxygenation during stabilization. The study addresses a long-standing evidence gap on early nCPAP pressure settings.
Impact: Provides pragmatic, trial-based guidance for initial nCPAP settings and escalation strategy during delivery-room stabilization of very preterm infants.
Clinical Implications: When very preterm infants fail to reach target SpO2 on nCPAP, clinicians should consider increasing PEEP (end-expiratory pressure) before raising FiO2, starting from around 6 cmH2O.
Key Findings
- Starting nCPAP at 6 cmH2O was supported as an initial approach in the delivery room.
- If target oxygen saturation is not reached, increasing PEEP should be prioritized over increasing oxygen concentration.
- The trial was prospectively registered (NCT05031650); deidentified individual participant data will not be shared.
Methodological Strengths
- Randomized controlled trial design with prospective registration
- Pragmatic delivery-room setting directly applicable to clinical practice
Limitations
- Sample size and effect estimates are not detailed in the abstract
- Potential single-center design and limited blinding information
- Individual participant data will not be shared, limiting reproducibility
Future Directions: Report full effect sizes, adverse events, and long-term respiratory outcomes; compare standardized PEEP protocols across centers to refine delivery-room nCPAP strategies.
UNLABELLED: The study aimed to compare the effects of individualized nasal continuous positive airway pressure (nCPAP) therapy using different positive end-expiratory pressure (PEEP) levels on heart rate, SpO CONCLUSION: This randomized clinical trial evaluated the effects of different PEEP levels in the delivery room management of very preterm infants. Initiating CPAP support at 6 cmH TRIAL REGISTRATION: Open lung strategy during non-invasive respiratory support of very preterm infants in the delivery room (OpenCPAP-DR), NCT05031650, 26 August 2021 https://clinicaltrials.gov/study/NCT05031650?term=Nuray%20duman&rank=1 , deidentified individual participant data will not be made available. WHAT IS KNOWN: • There is no specific evidence-based pressure level for early nCPAP recommended in the delivery room for very preterm infants. WHAT IS NEW: • When stabilizing very preterm infants in the delivery room, it has been found prudent to increase pressure rather than increase oxygen first when using nCPAP if the target oxygen saturation is not reached.
2. Assessment of the efficacy of Chinese herbal medicine combined with western medicine for treating severe acute pancreatitis-related acute lung injury/acute respiratory distress syndrome: a systematic review and meta-analysis based on randomized controlled trials.
Across 13 RCTs (917 patients), adding CHM to Western care for SAP-ALI/ARDS improved clinical response, reduced TNF-α and IL-6, and shortened time to pain relief and ICU stay, but did not reduce mortality. Study quality issues (blinding, allocation concealment) temper confidence in effect size.
Impact: Synthesizes RCT evidence on integrated therapy for SAP-associated ALI/ARDS, identifying meaningful improvements in inflammatory and clinical surrogates despite neutral mortality.
Clinical Implications: CHM plus standard care may be considered to improve short-term clinical surrogates in SAP-ALI/ARDS where expertise and quality-assured formulations exist, while counseling patients that mortality benefit is unproven.
Key Findings
- Clinical efficacy improved with CHM + Western medicine (RR 1.26, 95% CI 1.17–1.37).
- Inflammatory markers decreased (TNF-α MD −18.18 pg/mL; IL-6 MD −24.70 pg/mL; both P < 0.00001).
- Disease progression metrics improved (time to abdominal pain relief MD −1.56 days; ICU stay MD −3.27 days).
- No mortality difference was observed (RR 0.47; P = 0.96).
- Review registered in PROSPERO (CRD42024579735) and used Cochrane Risk of Bias Tool.
Methodological Strengths
- Comprehensive search across 12 databases with RCT-only inclusion
- Prospective registration (PROSPERO) and use of Cochrane Risk of Bias Tool
Limitations
- Methodological rigor of many included RCTs was limited (blinding and allocation concealment often unclear)
- Heterogeneity of CHM formulations and protocols may limit generalizability
- Mortality benefit was not demonstrated
Future Directions: Conduct larger, rigorously blinded, multi-center RCTs with standardized CHM formulations; elucidate mechanisms and assess long-term outcomes beyond hospitalization.
PURPOSE: This systematic review and meta-analysis aimed to evaluate the efficacy of Chinese herbal medicine (CHM) combined with Western medicine (WM) for treating severe acute pancreatitis-related acute lung injury/acute respiratory distress syndrome (SAP-ALI/ARDS). METHODS: A comprehensive search of 12 English and Chinese databases yielded 13 randomized controlled trials (RCTs) involving 917 patients. The experimental group received CHM compounds combined with standard WM, while the control group received only WM. Outcomes included clinical efficacy, inflammatory markers (e.g., TNF-α, IL-6), disease progression indicators (e.g., time to abdominal pain relief, ICU stay), and mortality rates. The Cochrane Risk of Bias Tool was used to assess study quality, and meta-analysis was conducted using RevMan 5.4. RESULTS: The meta-analysis demonstrated that CHM combined with WM significantly improved clinical efficacy (RR = 1.26, 95% CI: 1.17-1.37, P < 0.00001), reduced inflammatory markers (e.g., TNF-α: MD = -18.18 pg/mL, P < 0.00001; IL-6: MD = -24.70 pg/mL, P < 0.00001), and shortened disease progression indicators (e.g., time to abdominal pain relief: MD = -1.56 days, P < 0.00001; ICU stay: MD = -3.27 days, P < 0.00001). However, no significant difference in mortality rates was observed (RR = 0.47, P = 0.96). CONCLUSION: This study provides robust evidence that the combination of Chinese herbal medicine with Western medicine significantly enhances clinical outcomes for patients with SAP-ALI/ARDS. The findings highlight improvements in inflammatory markers, disease progression indicators, and oxygenation indices. However, the lack of significant differences in mortality rates and the limited methodological rigor of included studies (e.g., blinding and allocation concealment) are notable limitations. Future research should focus on optimizing RCT designs, exploring molecular mechanisms, and investigating long-term outcomes to strengthen the evidence base for integrated therapies. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, identifer CRD42024579735.
3. The Additional Prognostic Value of Serial Biomarker Measurements for Extubation Failure Among Patients With COVID-19 Acute Respiratory Distress Syndrome.
In 297 COVID-19 ARDS patients, 21.5% had extubation failure. Pre-extubation Hs-TnT, NT-proBNP, and PCT levels were higher in failures, but serial trajectories over the preceding days did not improve prediction; combined biomarker models added little discriminative value.
Impact: Clarifies that short-term serial biomarker trajectories offer limited added prognostic value for extubation readiness in ARDS, guiding resource use and clinical decision-making.
Clinical Implications: Reliance on daily pre-extubation trajectories of Hs-TnT, NT-proBNP, PCT, and IL-6 is unlikely to improve prediction of extubation failure; focus should remain on clinical assessment and validated weaning indices.
Key Findings
- Among 297 COVID-19 patients, 21.5% experienced extubation failure (reintubation or death within 7 days).
- Pre-extubation Hs-TnT, NT-proBNP, and PCT levels were consistently higher in patients with extubation failure.
- Changes over time (3 days before extubation) in the four biomarkers did not relate to extubation outcomes.
- Serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 added little prognostic information beyond single measurements.
Methodological Strengths
- Daily biomarker collection up to 3 days before extubation
- Use of linear mixed-effects models and logistic regression for trajectory and discrimination analyses
Limitations
- Retrospective design with potential confounding and selection biases
- Limited biomarker panel and short pre-extubation window
- Generalizability may be limited to COVID-19 ARDS populations
Future Directions: Prospective multi-center studies integrating physiologic weaning indices, imaging, and broader biomarker panels may better stratify extubation risk.
BACKGROUND: Extubation failure is associated with adverse outcomes in critically ill patients. While single biomarker measurements can aid prediction, repeated biomarker measurements can help to timely recognize underlying diseases. OBJECTIVES: The aim of this study was to investigate the temporal evolution of cardiac (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [Hs-TnT]) and inflammatory biomarkers (interleukin-6 [IL-6] and procalcitonin [PCT]) prior to extubation and determine their additional prognostic value. DESIGN: Retrospective cohort study. METHODS: Patients with COVID-19 extubated after mechanical ventilation were included. Daily biomarker levels were collected up to 3 days before extubation. The primary endpoint was extubation failure, defined as reintubation or death within 7 days. Linear mixed-effect models were used to analyze biomarker trajectories in patients with extubation success and failure. Each day before extubation a logistic regression model (consisting of the 4 biomarkers) was constructed to determine the model with the best discriminative ability. RESULTS: Among 297 patients, 21.5% experienced extubation failure. Log CONCLUSION: Hs-TnT, NT-proBNP and PCT measured on the days before extubation are consistently higher in patients with extubation failure. However, there was no relation between the change in biomarker levels over time and extubation outcome. The serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 do not seem to add prognostic information to predict extubation failure.